HLA-DQA1 Protein (AA 24-213, Extracellular) (His tag)

Produktnummer ABIN5712946

Produktdetails

Target: HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ alpha 1 (HLA-DQA1))

Protein-Typ: Recombinant

Proteineigenschaft: Extracellular, AA 24-213

Spezies: Human

Quelle: Escherichia coli (E. coli)

Aufreinigungstag / Konjugat: Dieses HLA-DQA1 Protein ist gelabelt mit His tag.

Applikation: SDS-PAGE (SDS)

Sequenz: EDIVADHVAS YGVNLYQSYG PSGQYTHEFD GDEQFYVDLG RKETVWCLPV LRQFRFDPQF ALTNIAVLKH NLNSLIKRSN STAATNEVPE VTVFSKSPVT LGQPNILICL VDNIFPPVVN ITWLSNGHSV TEGVSETSFL SKSDHSFFKI SYLTLLPSAE ESYDCKVEHW GLDKPLLKHW EPEIPAPMSE

Aufreinigung: SDS-PAGE

Reinheit: > 90 %

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.1-2 mg/mL

Buffer: 20 mM Tris-HCl based buffer, pH 8.0

Lagerung: -80 °C,4 °C,-20 °C

Informationen zur Lagerung: Store at -20°C, for extended storage, conserve at -20°C or -80°C. Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Antigendetails

Target: HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ alpha 1 (HLA-DQA1))

Andere Bezeichnung: DQA1 (HLA-DQA1 Produkte)

Synonyme: CD Protein, CELIAC1 Protein, DQ-A1 Protein, GSE Protein, HLA-DQA Protein, BoLA-DQA Protein, hla-dqa1 Protein, major histocompatibility complex, class II, DQ alpha 1 Protein, major histocompatibility complex, class II, DQ alpha, type 1 Protein, major histocompatibility complex, class II, DQ alpha 1 L homeolog Protein, HLA-DQA1 Protein, BOLA-DQA1 Protein, hla-dqa1.L Protein

Hintergrund: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents th on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As mbrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal syst where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The roval of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell mbrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Molekulargewicht: 25.5 kDa

UniProt: P01909

Pathways: T-Zell Rezeptor Signalweg, Cancer Immune Checkpoints